Table 1.
Pulmonary exacerbation treatment event demographics by Pa coverage category
| Pa Coverage | Complete | None | Incomplete | Indeterminant | All |
|---|---|---|---|---|---|
| Pulmonary exacerbation treatment events | |||||
| N (%)a | 2390 (62.6%) | 340 (8.9%) | 90 (2.4%) | 1000 (26.2%) | 3820 |
| Males, N (%) | 1163 (48.7%) | 138 (40.6%) | 52 (57.8%) | 420 (42.0%) | 1773 (46.4%) |
| Age at exacerbation, years | |||||
| Mean (SD) | 25.6 (11.8) | 27.9 (13.2) | 27.8 (11.5) | 24.7 (12.2) | 25.7 (12.0) |
| Median (IQR) | 23.5 (17.1, 32.3) | 25.1 (17.0, 37.0) | 24.7 (18.4, 36.9) | 22 (15.8, 31.1) | 23.4 (16.8, 32.6) |
| <18 years, N (%) | 710 (29.7%) | 96 (28.2%) | 20 (22.2%) | 332 (33.2%) | 1158 (30.3%) |
| 18 to 24 years, N (%) | 591 (24.7%) | 69 (20.3%) | 27 (30.0%) | 253 (25.3%) | 940 (24.6%) |
| 25 to 39 years, N (%) | 784 (32.8%) | 103 (30.3%) | 26 (28.9%) | 289 (28.9%) | 1202 (31.5%) |
| 40+ years, N (%) | 305 (12.8%) | 72 (21.2%) | 17 (18.9%) | 126 (12.6%) | 520 (13.6%) |
| Average (6-month) pre-treatment ppFEV1 | |||||
| Mean (SD) | 58.1 (23.2) | 60.7 (20.8) | 58.5 (20.9) | 69.2 (22.4) | 61.3 (23.2) |
| Median (IQR) | 56.4 (39.2, 75.3) | 60.6 (44.2, 76.9) | 58.3 (42.7, 70.4) | 71.1 (51.9, 87) | 62.3 (42.5, 78.7) |
| 100+, N (%) | 103 (4.3%) | 9 (2.6%) | 5 (5.6%) | 70 (7.0%) | 187 (4.9%) |
| 70 to <100, N (%) | 651 (27.2%) | 112 (32.9%) | 18 (20.0%) | 446 (44.6%) | 1227 (32.1%) |
| 40 to <70, N (%) | 1022 (42.8%) | 152 (44.7%) | 48 (53.3%) | 371 (37.1%) | 1593 (41.7%) |
| <40, N (%) | 614 (25.7%) | 67 (19.7%) | 19 (21.1%) | 113 (11.3%) | 813 (21.3%) |
| Average (6-month) pre-treatment BMI, kg/m2 | |||||
| Mean (SD) | 20.1 (3.7) | 20.5 (3.5) | 21.4 (3.3) | 20.7 (3.9) | 20.3 (3.8) |
| Median (IQR) | 19.7 (17.4, 21.9) | 20.2 (18.2, 22.1) | 21.3 (19.4, 23) | 20.2 (18.2, 22.5) | 19.9 (17.8, 22.1) |
| Antimicrobial treatment duration, days | |||||
| Mean (SD) | 34.6 (30.3) | 19.7 (12) | 21.4 (12.8) | 28 (16.1) | 31.3 (26.1) |
| Median (IQR) | 24 (17, 40) | 21 (14, 21) | 21 (14, 21) | 23 (21, 30) | 22 (18, 34) |
| 3 to 8 days, N (%) | 37 (1.5%) | 47 (13.8%) | 6 (6.7%) | 18 (1.8%) | 108 (2.8%) |
| 9 to 16 days, N (%) | 521 (21.8%) | 79 (23.2%) | 22 (24.4%) | 137 (13.7%) | 759 (19.9%) |
| 17 to 21 days, N (%) | 489 (20.5%) | 130 (38.2%) | 43 (47.8%) | 312 (31.2%) | 974 (25.5%) |
| 22 to 42 days, N (%) | 804 (33.6%) | 67 (19.7%) | 14 (15.6%) | 416 (41.6%) | 1301 (34.1%) |
| 43+ days, N (%) | 539 (22.6%) | 17 (5.0%) | 5 (5.6%) | 117 (11.7%) | 678 (17.7%) |
| Antipseudomonal antimicrobial administration routeb | |||||
| Oral, N (%) | 1314 (55.0%) | 183 (53.8%) | 69 (76.7%) | 783 (78.3%) | 2349 (61.5%) |
| Inhaled, N (%) | 767 (32.1%) | 0 (0.0%) | 0 (0.0%) | 444 (44.4%) | 1211 (31.7%) |
| Intravenous, N (%) | 1757 (73.5%) | 18 (5.3%) | 22 (24.4%) | 84 (8.4%) | 1881 (49.2%) |
| Mean span, days (SD) | 25.1 (24.1) | 16.6 (5.8) | 15.1 (7.2) | 21.4 (17.1) | 24.8 (23.6) |
| Median span, days (IQR) | 19 (14, 27) | 16 (13, 18) | 13.5 (12, 20) | 17 (12, 23) | 18 (14, 26) |
| Nonec, N (%) | - | 141 (41.5%) | - | - | 141 (3.7%) |
| Elapsed time from treatment end to maximum (3-month) post-treatment ppFEV1 | |||||
| N (%) | 2315 (96.9%) | 326 (95.9%) | 82 (91.1%) | 970 (97.0%) | 3693 (96.7%) |
| Mean (SD) | 60.5 (23) | 58.1 (23.6) | 57.8 (21.8) | 58.2 (23.6) | 59.7 (23.2) |
| Median (IQR) | 65 (44, 80) | 62 (42, 79) | 61 (42, 76) | 63 (42, 78) | 64 (43, 79) |
a.
Percentages are row totals relative to all treatment events studied
b.
Treatment events could include more than one route of antimicrobial administration
c.
Treatment events consisting entirely of antimicrobials considered inactive against P. aeruginosa
SD = standard deviation, IQR = interquartile range, ppFEV1=percent predicted forced expiratory volume in 1 sec. Percentages are column totals unless otherwise noted